Park Place Capital Corp Trims Stake in Humana Inc. (NYSE:HUM)

Park Place Capital Corp lowered its stake in shares of Humana Inc. (NYSE:HUM) by 42.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 988 shares of the insurance provider’s stock after selling 743 shares during the quarter. Park Place Capital Corp’s holdings in Humana were worth $313,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of HUM. Mendota Financial Group LLC grew its holdings in Humana by 9.2% in the second quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock worth $119,000 after purchasing an additional 27 shares during the period. Aurora Investment Counsel grew its holdings in Humana by 1.3% in the fourth quarter. Aurora Investment Counsel now owns 2,273 shares of the insurance provider’s stock worth $1,155,000 after purchasing an additional 29 shares during the period. Capital Advisors Ltd. LLC grew its holdings in Humana by 17.0% in the second quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock worth $80,000 after purchasing an additional 31 shares during the period. EP Wealth Advisors LLC grew its holdings in Humana by 1.6% in the fourth quarter. EP Wealth Advisors LLC now owns 2,294 shares of the insurance provider’s stock worth $1,050,000 after purchasing an additional 37 shares during the period. Finally, CarsonAllaria Wealth Management Ltd. grew its holdings in Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after purchasing an additional 39 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Up 2.9 %

HUM opened at $243.20 on Wednesday. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $530.54. The company has a market capitalization of $29.31 billion, a PE ratio of 15.14, a PEG ratio of 2.44 and a beta of 0.50. The firm’s 50 day simple moving average is $334.58 and its two-hundred day simple moving average is $342.37.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, topping the consensus estimate of $5.89 by $1.07. The business had revenue of $29.54 billion for the quarter, compared to the consensus estimate of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The company’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the firm earned $8.94 earnings per share. As a group, equities analysts forecast that Humana Inc. will post 16.01 EPS for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be paid a $0.885 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.46%. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Leerink Partnrs cut shares of Humana from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Sanford C. Bernstein upgraded shares of Humana from a “market perform” rating to an “outperform” rating and set a $308.00 target price on the stock in a research note on Tuesday. Stephens downgraded shares of Humana from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $400.00 to $250.00 in a research note on Wednesday, October 2nd. Jefferies Financial Group downgraded shares of Humana from a “buy” rating to a “hold” rating and dropped their target price for the stock from $519.00 to $253.00 in a research note on Monday. Finally, TD Cowen downgraded shares of Humana from a “buy” rating to a “hold” rating and dropped their target price for the stock from $402.00 to $261.00 in a research note on Monday. One research analyst has rated the stock with a sell rating, eighteen have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Humana currently has an average rating of “Hold” and a consensus price target of $324.86.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.